HomeMarket NewsBernstein Begins Coverage of Moderna (LSE:0A45) with Neutral Rating

Bernstein Begins Coverage of Moderna (LSE:0A45) with Neutral Rating

Daily Market Recaps (no fluff)

always free

Bernstein Starts Coverage on Moderna, Anticipating Significant Growth

On October 17, 2024, Bernstein initiated coverage of Moderna (LSE:0A45) with a Market Perform recommendation.

Analysts Predict Substantial Upside Potential

As of September 25, 2024, the average one-year price target for Moderna stands at 104.19 GBX/share. Predictions vary, with a low estimate of 46.55 GBX and a high of 250.39 GBX. This average price target indicates a potential increase of 78.97% from its latest closing price of 58.22 GBX/share.

Projected Revenue Growth

Moderna is expecting a projected annual revenue of 6,692MM, which reflects an increase of 32.51%. However, the anticipated annual non-GAAP EPS is -3.39.

Investor Sentiment and Holdings

A total of 1,640 funds and institutions currently report positions in Moderna, marking an increase of 2.18% (35 new owners) from the previous quarter. The average portfolio weight for all funds dedicated to 0A45 is 0.28%, up by 2.10%. Over the past three months, total shares owned by institutions have risen by 2.70%, reaching 276,183K shares.

Changes in Major Shareholders

GB:0A45 / Moderna, Inc. Shares Held by Institutions

Baillie Gifford holds 43,449K shares, or 11.30% of Moderna, reporting a decrease of 2.78% from its previous holding of 44,656K shares. Despite this reduction, the firm increased its allocation in 0A45 by 8.60% last quarter.

VTSMX, the Vanguard Total Stock Market Index Fund Investor Shares, holds 10,907K shares, which is 2.84% of the company. This represents a slight increase of 0.98% from the previous filing of 10,801K shares, with the firm boosting its allocation in 0A45 by 9.44% over the last quarter.

VWIGX, the Vanguard International Growth Fund Investor Shares, has 9,029K shares, representing 2.35% ownership, experiencing a decrease of 1.35% from the prior report of 9,151K shares, though it increased its allocation in 0A45 by 49.46% last quarter.

Meanwhile, VFINX, the Vanguard 500 Index Fund Investor Shares, holds 8,558K shares, equating to 2.23% ownership. This marks an increase of 2.31% from 8,359K shares previously, and the firm raised its allocation in 0A45 by 7.99% last quarter.

Lastly, VIMSX of the Vanguard Mid-Cap Index Fund Investor Shares has 7,388K shares, representing 1.92% of Moderna. This shows a slight decrease of 0.91% from its previous holding of 7,456K shares, although the firm did increase its allocation in 0A45 by 14.00% last quarter.

Fintel serves as a comprehensive platform for investing research, catering to individual investors, traders, financial advisors, and small hedge funds.

Our extensive data covers fundamentals, analyst reports, ownership data, fund sentiment, options trading, and much more, alongside stock selection powered by advanced quantitative models.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Do you want a daily market summary with no fluff?

Simple Straightforward Daily Stock Market Recaps Sent for free,every single trading day: Read Now

Explore More

Simple Straightforward Daily Stock Market Recaps

Get institutional-level analysis to take your trading to the next level, sign up for free and become apart of the community.